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Abstract
We describe a new PDGFRB fusion associated with a t(5;14)(q33;q24)
in a patient with a longstanding chronic myeloproliferative disorder with
eosinophilia. After confirmation of PDGFRB involvement and definition
of the chromosome 14 breakpoint by fluorescence in situ hybridization,
candidate partner genes were selected on the basis of the presence of
predicted oligomerization domains believed to be an essential feature of
tyrosine kinase fusion proteins. We demonstrate that the t(5;14) fuses
PDGFRB to NIN, a gene encoding a centrosomal protein with CEP110-
like function. After treatment with imatinib, the patient achieved hema-
tological and cytogenetical remission, but NIN-PDGFRB mRNA remained
detectable by reverse transcription-PCR.
Introduction
BCR-ABL-negative chronic myeloid leukemia is a term used to
encompass a heterogeneous group of relatively uncommon diseases
that includes atypical chronic myeloid leukemia (CML), chronic eosin-
ophilic leukemia (CEL), and overlaps with at least a subset of patients
with chronic myelomonocytic leukemia. Within the WHO classifica-
tion, these patients either fall into the myelodysplastic/myeloprolifer-
ative disease or chronic myeloproliferative disorders groups, depend-
ing on whether or not they show dysplastic features (1). In general,
unlike CML with the BCR-ABL fusion, the molecular events that give
rise to these diseases is poorly understood, but reciprocal chromo-
somal translocations that disrupt genes encoding receptor tyrosine
kinases, notably PDGFRB at 5q31-33 and FGFR1 at 8p11, have been
found in some patients. As a consequence of these translocations,
constitutively active fusion proteins that are functionally and struc-
turally analogous to BCR-ABL are produced (2). Clinically, FGFR1
rearrangements are associated with the 8p11 myeloproliferative syn-
drome/stem cell leukemia-lymphoma syndrome (2) and the clinical
phenotype associated with PDGFRB rearrangements has also been
suggested as a discrete disease entity (3). These patients present with
a CML/chronic myelomonocytic leukemia-like disease, usually with
prominent eosinophilia an often with monocytosis and/or splenomeg-
aly. Only a few progress to acute myeloid leukemia and the latency is
highly variable. The extremely male bias in affected patients remains
a striking and unexplained feature and finally it has been shown that
PDGFRB-positive patients respond well to treatment with imatinib
mesylate (4–7) although this drug is inactive against FGFR1 fusions
(8). Consequently, identification of patients with PDGFRB rearrange-
ments is very important for their clinical management. Rearrangement
of PDGFRB was first described in patients with the t(5;12)(q31;p12),
leading to the formation of the ETV6-PDGFRB fusion (9). Subse-
quently, PDGFRB has been found fused to CEV14/TRIP11 by the
t(5;14)(q31;p12) (Ref. 10); HIP1 by the t(5;7)(q33;q11.2) (Ref. 11);
H4/D10S170 by the t(5;10)(q33;q11-q21) (Refs. 12, 13); Rabaptin/
RABEP1 by the t(5;17)(q33;p13) (Ref. 14), and Myomegalin/
PDE4DIP by the t(1;5)(q23;q33) (Ref. 7). Here, we describe a new
PDGFRB rearrangement in a patient with a t(5;14)(q33;q24) and an
imatinib-responsive CML-like myeloproliferative disorder. We show
that this reciprocal translocation fuses PDGFRB to NIN, a gene
encoding a centrosomal protein with CEP110-like function.
Materials and Methods
Patient Clinical Data. A 35-year-old male was admitted to hospital in
September 1989 with severe pain and swelling in the right ankle. No fever and
no systemic symptoms were observed. He related a similar event 20 years
before that responded to nonsteroidal anti-inflammatory drugs and analgesia.
Normal color of skin and mucosae, functional incapacity of the right leg, and
no adenopathies were observed, but spleen enlargement was found by ultra-
sonography and computed tomography scan. Blood count showed 155 g/liter
hemoglobin and a WBC count of 52  109/liter with 37% segmented neutro-
phils, 28% band neutrophils, 5% metamyelocytes, 6% myelocytes, 13% eo-
sinophils, 1% basophils, 7% lymphocytes, and 3% monocytes. The platelet
count was 280  109/liter and neutrophil alkaline phosphatase activity was 2.
Bone marrow aspirate showed an increase in myelopoiesis and a prominent
eosinophila, and the karyotypic analysis showed a t(5;14)(q35;q24) in 100% of
the metaphases analyzed. On the basis of these data, a diagnosis of atypical
CML in chronic phase was made. Treatment with IFN (3 MU/day) was
prescribed, and major hematological response was achieved. In 1995 a new
painful episode of arthritis appeared that was interpreted as psoriasic arthritis
because of the appearance of suggestive skin lesions. Karyotypic analysis
showed persistence of t(5;14)(q35;q24) mitoses. Eosinophilia persisted, but no
splenomegaly was observed. In March 1996, hematological remission was
achieved again after treatment with IFN (5 MU/day), psoriasic lesions were
not observed, and IFN administration was subsequently ceased. In 1997,
moderate skin lesions were observed again with the WBC count progressively
increasing, with eosinophila, basophilia, and mild splenomegaly. The patient
refused IFN and was subsequently treated with hydroxyurea (1 g/day),
resulting in good hematological but not cytogenetical control. Reverse tran-
scription (RT)-PCR for BCR-ABL was negative (15). In May 2002, due to the
detection of PDGFRB involvement in the chromosomal rearrangement (16),
treatment with imatinib mesylate was instigated. The initial dose of 400
mg/day was not well tolerated, and the patient decided to stop. In February
2003, imatinib (at 200 mg/day) was given again, resulting in hematological and
cytogenetical remission but not complete molecular remission by RT-PCR (see
below). On the basis of these data, the dose of imatinib was raised to 400
mg/day in November 2003.
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FISH Analysis. Whole chromosome painting was performed using the
STAR*FISH human whole chromosome specific probes (Cambio, Cambridge,
United Kingdom), with probes for chromosome 5 and 14 labeled with Cy3 and
FITC, respectively. FISH analysis on bone marrow metaphases to narrow the
breakpoint on 14q24 were performed with bacterial artificial chromosomes
from the BACPAC Resource Center4 at Children’s Hospital Oakland Research
Institute (Oakland, CA) or from the Sanger Institute Mapping Core Group5 at
The Wellcome Trust Sanger Institute (Hinxton, United Kingdom). NIN gene
on chromosome 14 was studied with bacterial artificial chromosomes RPCI-11
286O18 (centromeric to NIN) and RPCI 248J18 (which covers almost the
whole gene). NIN clone positions were based on data provided by the Univer-
sity of California–Santa Cruz version hg16 (July 2003) available at the Uni-
versity of California–Santa Cruz Genome Browser.6
Southern Analysis of PDGFRB. Ten g of patient DNA and a control
DNA without 5q31-q33 rearrangement were digested with HindIII, BamHI,
EcoRI, and BglII, blotted using standard conditions and hybridized with an
813-bp 32P-dCTP-labeled PDGFRB intron 10 probe obtained by amplifica-
tion by PCR with primers PD3-C and PD3-D (Table 1) from normal human
genomic DNA.
PCR-Based Methods. 5-Rapid amplification of cDNA Ends was per-
formed with the GeneRacer kit (Invitrogen-Life Technologies, Inc., Paisley,
United Kingdom) according to the manufacturer’s instructions, using reverse
primers located in the PDGFRB exons 10, 11, 12, and 14 and total RNA
extracted using the RNeasy Mini kit (Qiagen, Hilden, Germany). Vectorette
libraries were generated with Universal Vectorette System (Sigma-Genosys,
The Woodlands, TX) and checked by PCR with the same primers. PCR and
RT-PCR were performed according to standard procedures and primers are
listed on Table 1. RT-PCR reactions to check the putative NIN-PDGFRB
translocation were carried out with Immolase DNA polymerase heat activated
(Bioline; London, United Kingdom) using NIN-1 to NIN-6 as forward primers
and PDGFRB-1 and PDGFRB-2 as reverse primers in separate and multiple
combinations. To amplify the genomic breakpoint, long PCR with JumpStart
REDAccuTaq LA DNA polymerase (Sigma-Aldrich Co, St. Louis, MO) from
genomic DNA was performed according to manufacturer’s instructions.
DNA Cloning and Sequencing. Fresh PCR products were cloned using the
TOPO TA Cloning kit for Sequencing (Invitrogen-Life Technologies, Inc.).
Colonies with recombinant plasmids containing PCR products were screened
by boiling-PCR insert amplification. Positive recombinant plasmids were
cultured again and plasmid DNA was extracted with QIAprep Spin Miniprep
kit (Qiagen), checked again by EcoRI digestion and sequenced with ABI
PRISM D-Rhodamine Terminator Cycle Sequencing kit (Applied Biosystems,
Foster City, CA) in an ABI PRISM 377 DNA Sequencer (Applied Biosystems,
Foster City, CA).
Computational Analysis. Search for candidate genes in the 14q21.1-q32
chromosomal region was done using EnsMart as data retrieval tool from data
held in the Ensembl database Human release 11.31.1 from March 2003 (built
around the National Center for Biotechnology Information 31 assembly).
Protein sequences were then analyzed using the pepcoil program from the
EMBOSS Package.7 Pepcoil predicts coiled-coil regions by calculating the
probability of a coiled-coil structure for windows of 28 residues through a
protein sequence using the method of Lupas et al. (17).
Results
Rearrangement of PDGFRB. We have previously used two-color
FISH analysis to show that the t(5;14) targets PDGFRB (16). Using
Southern blot hybridization, we identified rearranged bands with two
restriction enzymes (Fig. 1), thus confirming rearrangement of PDG-
FRB and furthermore that the breakpoint must lie in the vicinity of
intron 10, as found for all other fusions involving this gene. However,
multiple attempts to identify the putative PDGFRB 5-partner gene
using 5-rapid amplification of cDNA ends PCR and screening of
vectorette-based libraries were unsuccessful.
Identification of Candidate Partner Genes on Chromosome 14.
To narrow down the position of the chromosome 14 breakpoint we
performed FISH analysis on patient metaphases. We found that the
breakpoint was located between bacterial artificial chromosomes
RPCI-11 596C23 at 14q21.3 and RPCI-11 368A1 at 14q22.1, an
interval of 1 Mb that contains 13 RefSeq genes. Additional attempts
to refine the chromosome 14 breakpoint by FISH were unsuccessful.
PDGFRB translocation partner genes encode proteins with oligomer-
ization domains (most of them coiled-coil domains), an essential
feature required for the observed constitutive tyrosine kinase activity
of the fusion proteins (2). We therefore tested each gene in the interval
for their potential to encode proteins with coiled-coil domains, an
analysis that resulted in three candidates for involvement in the
t(5;14): SDCCAG1; SAV1 (SAlVador homologue 1 Drosophila); and
NIN. SDCCAG1, the gene for a Serologically Defined Colon Cancer
Antigen 1 codes for a putative nuclear protein with three coiled-coil
domains. SAV1 encodes a protein which contains two WW domains
and a coiled-coil region. Ninein, the product of the NIN gene, is a
centrosomal protein that is predicted to consist of coiled-coils
throughout most of its sequence. Its structure resembles that of an-
other centrosomal protein, CEP110, a known fusion partner of FGFR1
in 8p11 myeloproliferative syndrome (18). For this reason, we con-
sidered NIN as the most likely fusion partner in the t(5;14).
Identification of NIN-PDGFRB. To determine whether NIN was
fused to PDGFRB, we performed multiple PCR analyses on patient
and control cDNAs with forward primers located in several NIN exons
and reverse primers located in PDGFRB exons 12 and 14. Positive
results were obtained with forward primers located toward the 3-end
of NIN, sequencing of which showed an in-frame fusion between NIN
exon 28 and PDGFRB exon 12 (Fig. 2A1). The breakpoint was
confirmed by RT-PCR with different primer combinations (data not
shown) and also by amplifying the genomic breakpoint (Fig. 2A2).
The breakpoint position is consistent with the rearranged bands ob-
served by Southern analysis (Fig. 1). RT-PCR with primers PDG-
FRB-2b and NIN-7 showed very weak amplification of the predicted
reciprocal PDGFRB-NIN fusion, the identity of which was confirmed
by sequencing (Fig. 2A.3).
The fusion gene is predicted to encode a NIN-PDGFRB protein of
300 kDa (2595 amino acids) retaining most of NIN protein (2047 of
the wild-type 2116 amino acids) and most of the intracellular domain
of PDGFRB (548 amino acids), including the entire tyrosine kinase
domain (Fig. 2B). One unique aspect of the fusion is that the mRNA
junction involves PDGFRB exon 12, whereas all other reported PDG-
FRB fusion involve exon 11. Consequently, NIN-PDGFRB lacks the
PDGFRB transmembrane domain. From ninein, the fusion would
retain the potential GTP-binding site, a large coiled-coil domain, four
leucine-zipper domains, and a glycogen synthase kinase-3 binding
4 Internet address: http://www.chori.org/bacpac/.
5 Internet address: http://www.sanger.ac.uk/Teams/CloneRes.
6 Internet address: http://genome.ucsc.edu.
7 Internet address: http://www.hgmp.mrc.ac.uk/Software/EMBOSS/.
Table 1 Oligonucleotide primer sequences used in PCR assays
Primer Sequence (5 3 3) Gene Positiona
NIN-1 TACCAAGAACAGCATTCACCAGGCG NIN 1247–1271
NIN-2 GCGGCAGTGCAGGGTACTACAAGAC NIN 1763–1787
NIN-3 CGCCTGGACAGAAGAGAAGGTGAGAG NIN 2384–2409
NIN-4 GGAGGAAGAGCTGAAGGCAATGAT NIN 4601–4624
NIN-5 GTCCCGATCTCTCTGACTTCCAGCA NIN 5215–5239
NIN-6 TGCTTTGGCAAGAGAATGAGAGGCT NIN 5692–5716
NIN-7 TCCTTCACCATTGCGTCTGCCTTAGT NIN 6243–6267
NIN-8 GTCATGGAGGAACGAATGATAGAAG NIN 6345–6370
PD3-C AGGTGGGACAGGACTCCCTA PDGFRB
PD3-D TGGAGGCAGAGATGAGAGCA PDGFRB
PDGFRB-1 CACAGACTCAATCACCTTCCATCG PDGFRB 2049–2071
PDGFRB-2 GATATAGATGGGTCCTCCTTTGGTG PDGFRB 2369–2393
PDGFRB-2b ACGTACTGGGAGGAGGAGCAGGAGT PDGFRB 1797–1821
a Nucleotide positions are referred to GenBank accession numbers NM_020921 (NIN)
and NM_002609 (PDGFRB).
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site (19). The large size of the NIN portion retained in the fusion
explains the failure of 5-rapid amplification of cDNA ends because
the methodology we used was based on the selection of mature and
complete capped mRNAs.
Response to Imatinib Treatment. Once the partner gene was
identified, it was possible to monitor the molecular response to ima-
tinib mesylate using an RT-PCR assay with primers NIN-8 and
PDGFRB-2. Molecular detection of the fusion transcript was possible
in every available sample before imatinib treatment and also in May
2002, when treatment with imatinib mesylate was started and karyo-
type analysis showed 91% of metaphases with the translocation. As
described above, imatinib treatment was stopped but restarted in
February 2003. From April 2003, the patient was found to be in
cytogenetical remission (30 metaphases analyzed) but in November
2003 remained RT-PCR positive. On the basis of these data, the
imatinib dose was raised to 400 mg/day in November 2003. The
course of the patient is illustrated on Fig. 3.
Discussion
We have identified NIN, encoding the centrosomal-associated pro-
tein ninein, as the seventh gene that is fused to PDGFRB in hemato-
logical disorders. NIN shares features in common with other tyrosine
kinase fusion partners, namely widespread expression and the pres-
ence of putative oligomerization domains. Although we have no direct
experimental proof, it is likely that the NIN promoter drives expres-
sion of the chimeric gene in hemopoietic progenitor cells, and the
oligomerization domain(s) result in ligand-independent activation of
the PDGFRB kinase moiety by mimicking the normal process of
ligand-induced receptor dimerization.
NIN is the second centrosomal protein-encoding gene that is fused
to a tyrosine kinase in myeloproliferative diseases, the first being
CEP110, the partner of FGFR1 in 8p11 myeloproliferative syndrome
with the t(8;9)(p12;q33) (Ref. 18). In a typical somatic cell, the
centrosome is composed of a pair of centrioles surrounded by a mass
Fig. 2. A, molecular analyses (b) left: one-step reverse transcription (RT)-PCR ampli-
fication of the NIN-PDGFRB chimeric transcript (1004 bp) with primers NIN-6 and
PDGFRB-2. Right: sequence analysis of the amplification product showing the fusion
between NIN exon 28 and PDGFRB exon 12. (b) left: PCR amplification with primers
NIN-8 and PDGFRB-1 of the NIN-PDGFRB genomic fusion (2.5 Kb). Right: sequence
analysis of the amplification product showing the fusion between NIN intron 28 and
PDGFRB intron 11. (c) left: one-step RT-PCR amplification with primers PDGFRB-2b
and NIN-7 of the PDGFRB-NIN reciprocal chimeric transcript (272 bp). Right: sequence
analysis of the amplification product showing the fusion between PDGFRB exon 10 and
NIN exon 29. In all cases: Lane M, 1 kb plus DNA ladder molecular weight marker
(Invitrogen-Life Technologies, Inc.); Lane 1, cDNA or gDNA from the patient; Lane 2,
cDNA or gDNA from a normal donor; Lane 3, water. B, schematic representation of
PDGFRB, NIN, and the putative chimeric NIN-PDGFRB structures. TM, transmembrane
domain; TK, tyrosine-kinase domain; LZ leuzine-zipper domain. Coiled-coil domains on
NIN and NIN-PDGFRB are indicated with asterisks.
Fig. 1. Southern blot analysis. Southern blot of digested genomic DNA from bone
marrow of the patient, together with digested control genomic DNA, probed with an
813-bp fragment from PDGFRB intron 10 (). f indicates exons. Clearly rearranged
fragments are seen in EcoRI and BglII digests and are indicated with white asterisks on
the blot. A cartoon is shown below that explains the fragments detected and the restriction
sites indicate as  (the EcoRI 9.5 kb rearranged PDGFRB-NIN fragment versus the 17.4
Kb normal PDGFRB fragment, and the BgI II 3.2 kb rearranged PDGFRB-NIN fragment
versus the 7.5 Kb normal PDGFRB fragment).
Fig. 3. Hematological and cytogenetical course of the t(5;14) patient.
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of amorphous pericentriolar material that contain complexes of -
tubulin, centrin, pericentrin, and ninein. Ninein has been demonstrated
to play an important role in microtubule minus end capping, centriole
positioning, anchoring, and in centrosome maturation (19). Ninein
levels decline at metaphase and anaphase and reaccumulate at the
telophase-G1 transition of the next cell cycle; consequently, it has
been suggested that ninein might play a role in ensuring equal chro-
mosome segregation before telophase/cytokinesis (19). However, be-
cause no additional karyotypic changes appeared over 13 years, it is
unlikely that the t(5;14)-positive cells in this patient had centrosome
abnormalities and genetic instability as a consequence of ninein
involvement.
Six of the seven PDGFRB fusions described to date have been
found in patients with chronic eosinophilic leukemia, atypical CML,
or chronic myelomonocytic leukemia, with eosinophilia using being
present (3). CEV14-PDGFRB, associated with the t(5;14)(q31;p12), is
the exception, having only been found as a secondary event in a
patient with relapsed acute myeloid leukemia. As in the case described
here, some patients also displayed skin lesions, and it is conceivable
that these arise as a consequence of aberrant PDGFRB signaling
because this receptor is normally involved in wound healing and
repair of skin lesions. Alternatively, these skin lesions may be a
consequence of eosinophilic infiltrations (3).
Identification of patients with PDGFRB rearrangements is impor-
tant because they respond well to treatment with imatinib mesylate
(4–7). In these studies, patients were most commonly treated with 400
mg/day of imatinib as a standard dose, although in some cases, it was
necessary to increase it (4–7). Our patient achieved hematological and
cytogenetical remission with imatinib mesylate at 200 mg/day, but on
finding expression of NIN-PDGFRB by single-step PCR after 6
months of treatment, the dose of imatinib was raised to 400 mg/day.
In summary, we have a described a myeloproliferative disease
patient with a novel PDGFRB fusion gene, identified in part by
bioinformatic techniques. Characterization of the translocation en-
abled the patient to be treated by signal transduction therapy and for
that treatment to be tailored by monitoring the molecular response.
The partner gene, NIN, is functionally related to CEP110, supporting
the concept of a network of tyrosine kinases and partners giving rise
to CML-like diseases (2).
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